MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

103.54
+2.08
+2.05%
After Hours: 103.67 +0.13 +0.13% 18:38 05/11 EDT
OPEN
96.76
PREV CLOSE
101.46
HIGH
106.35
LOW
95.11
VOLUME
2.40M
TURNOVER
--
52 WEEK HIGH
220.20
52 WEEK LOW
54.00
MARKET CAP
7.85B
P/E (TTM)
-18.4094
1D
5D
1M
3M
1Y
5Y
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics company reported strong earnings on Tuesday.
Benzinga · 24m ago
Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer
Benzinga · 4d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Alcon (ALC) and Karuna Therapeutics (KRTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP), Alcon (ALC) and Karuna
SmarterAnalyst · 5d ago
CRISPR Therapeutics, Nkarta to collaborate on cancer therapies
CRISPR Therapeutics (CRSP) and Nkarta (NKTX) aim to develop CRISPR/Cas9 gene-edited cell therapies for cancer.Under a new collaboration, the two companies will develop and commercialize two CAR NK cell product candidates:
Seekingalpha · 5d ago
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
-Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities- -Companies to co-develop and co-commercialize
Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities- -Companies to co-develop and co-commercialize · 5d ago
BRIEF-CRISPR Therapeutics And Nkarta Announce Global Collaboration To Develop Gene-Edited Cell Therapies For Cancer
reuters.com · 5d ago
Global Gene Editing Service MarketSize, Share, Value, and Competitive Landscape 2020
May 04, 2021 (Heraldkeepers) -- Global Gene Editing Service Market Overview:Global Gene Editing Service Market Report 2020 comes with the extensive industry...
Heraldkeepers · 05/05 00:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRSP. Analyze the recent business situations of Crispr Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRSP stock price target is 160.00 with a high estimate of 220.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 489
Institutional Holdings: 49.80M
% Owned: 65.72%
Shares Outstanding: 75.77M
TypeInstitutionsShares
Increased
128
4.72M
New
135
912.28K
Decreased
89
3.49M
Sold Out
38
2.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/President/Co-Founder/Director
Rodger Novak
Chief Executive Officer/Director
Samarth Kulkarni
Chief Financial Officer
Michael Tomsicek
Chief Operating Officer
Lawrence Klein
Executive Vice President
Tony Ho
General Counsel/Secretary
James Kasinger
General Counsel/Secretary
Jim Kasinger
Other
Philippe Drouet
Independent Director
Ali Behbahani
Independent Director
Bradley Bolzon
Independent Director
Simeon George
Independent Director
John Greene
Independent Director
Katherine High
No Data
  • All
  • Financials
  • Insiders
More
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Webull offers kinds of Crispr Therapeutics AG stock information, including NASDAQ:CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.